TR201902023T4 - Smac mimetikleri olarak 6-alkinil-piridin türevleri. - Google Patents

Smac mimetikleri olarak 6-alkinil-piridin türevleri. Download PDF

Info

Publication number
TR201902023T4
TR201902023T4 TR2019/02023T TR201902023T TR201902023T4 TR 201902023 T4 TR201902023 T4 TR 201902023T4 TR 2019/02023 T TR2019/02023 T TR 2019/02023T TR 201902023 T TR201902023 T TR 201902023T TR 201902023 T4 TR201902023 T4 TR 201902023T4
Authority
TR
Turkey
Prior art keywords
alkynyl
smac mimetics
pyridine derivatives
smac
mimetics
Prior art date
Application number
TR2019/02023T
Other languages
English (en)
Turkish (tr)
Inventor
Reiser Ulrich
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of TR201902023T4 publication Critical patent/TR201902023T4/tr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
TR2019/02023T 2014-08-11 2015-08-10 Smac mimetikleri olarak 6-alkinil-piridin türevleri. TR201902023T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14180554 2014-08-11

Publications (1)

Publication Number Publication Date
TR201902023T4 true TR201902023T4 (tr) 2019-03-21

Family

ID=51300621

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/02023T TR201902023T4 (tr) 2014-08-11 2015-08-10 Smac mimetikleri olarak 6-alkinil-piridin türevleri.

Country Status (34)

Country Link
US (4) US9481673B2 (cg-RX-API-DMAC7.html)
EP (1) EP3180339B1 (cg-RX-API-DMAC7.html)
JP (1) JP6250226B2 (cg-RX-API-DMAC7.html)
KR (1) KR102445744B1 (cg-RX-API-DMAC7.html)
CN (2) CN111440164B (cg-RX-API-DMAC7.html)
AP (1) AP2017009718A0 (cg-RX-API-DMAC7.html)
AR (1) AR101479A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015303308B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017002498B1 (cg-RX-API-DMAC7.html)
CA (1) CA2956123C (cg-RX-API-DMAC7.html)
CL (1) CL2017000326A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017001226A2 (cg-RX-API-DMAC7.html)
CY (1) CY1121273T1 (cg-RX-API-DMAC7.html)
DK (1) DK3180339T3 (cg-RX-API-DMAC7.html)
EA (1) EA031424B1 (cg-RX-API-DMAC7.html)
ES (1) ES2711763T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20190336T1 (cg-RX-API-DMAC7.html)
HU (1) HUE043915T2 (cg-RX-API-DMAC7.html)
IL (1) IL249844B (cg-RX-API-DMAC7.html)
LT (1) LT3180339T (cg-RX-API-DMAC7.html)
ME (1) ME03303B (cg-RX-API-DMAC7.html)
MX (1) MX2017001835A (cg-RX-API-DMAC7.html)
NZ (1) NZ728073A (cg-RX-API-DMAC7.html)
PE (1) PE20170193A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017500231A1 (cg-RX-API-DMAC7.html)
PL (1) PL3180339T3 (cg-RX-API-DMAC7.html)
PT (1) PT3180339T (cg-RX-API-DMAC7.html)
RS (1) RS58355B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201700999YA (cg-RX-API-DMAC7.html)
SI (1) SI3180339T1 (cg-RX-API-DMAC7.html)
TR (1) TR201902023T4 (cg-RX-API-DMAC7.html)
TW (1) TWI723959B (cg-RX-API-DMAC7.html)
UA (1) UA118887C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016023858A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR101479A1 (es) * 2014-08-11 2016-12-21 Boehringer Ingelheim Int Derivados de 6-alquinil-piridina
CN109153645B (zh) * 2016-05-19 2022-06-21 勃林格殷格翰国际有限公司 制备6-炔基-吡啶衍生物的方法
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
BR112019016737A2 (pt) * 2017-03-31 2020-03-31 Boehringer Ingelheim International Gmbh Terapia anticâncer combinada
EP3886842A1 (en) 2018-11-26 2021-10-06 Debiopharm International SA Combination treatment of hiv infections
TWI894135B (zh) * 2019-01-25 2025-08-21 德商百靈佳殷格翰國際股份有限公司 編碼ccl21之重組棒狀病毒
JP2022550037A (ja) 2019-09-25 2022-11-30 デバイオファーム インターナショナル エス.エー. 局所進行性扁平上皮癌を有する患者の治療のための投与レジメン
AU2021285068A1 (en) 2020-06-03 2023-01-19 Boehringer Ingelheim International Gmbh Recombinant rhabdovirus encoding for a CD80 extracellular domain Fc-fusion protein
WO2024175554A1 (en) 2023-02-21 2024-08-29 Institut Curie Trail agonists for use in the treatment of cancer in patients having an activating alteration of fgfr3

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060234360A1 (en) 2005-04-13 2006-10-19 Paola Branduardi Ascorbic acid production from D-glucose in yeast
CN101193908B (zh) 2005-06-08 2012-04-11 诺瓦提斯公司 有机化合物
WO2007101347A1 (en) 2006-03-07 2007-09-13 Aegera Therapeutics Inc. Bir domain binding compounds
EP2086938B1 (en) * 2006-12-07 2012-01-25 Novartis AG Organic compounds
US8859541B2 (en) 2012-02-27 2014-10-14 Boehringer Ingelheim International Gmbh 6-alkynylpyridines
US9249151B2 (en) 2013-08-23 2016-02-02 Boehringer Ingelheim International Gmbh Bis-amido pyridines
US9278978B2 (en) 2013-08-23 2016-03-08 Boehringer Ingelheim International Gmbh 6-Alkynyl Pyridine
AR101479A1 (es) * 2014-08-11 2016-12-21 Boehringer Ingelheim Int Derivados de 6-alquinil-piridina

Also Published As

Publication number Publication date
PT3180339T (pt) 2019-02-27
CN111440164B (zh) 2023-02-17
PE20170193A1 (es) 2017-03-25
KR20170036095A (ko) 2017-03-31
ME03303B (me) 2019-07-20
SI3180339T1 (sl) 2019-03-29
TWI723959B (zh) 2021-04-11
RS58355B1 (sr) 2019-03-29
CA2956123A1 (en) 2016-02-18
JP6250226B2 (ja) 2017-12-20
TW201619156A (zh) 2016-06-01
US20160039814A1 (en) 2016-02-11
PL3180339T3 (pl) 2019-05-31
US9481673B2 (en) 2016-11-01
HRP20190336T1 (hr) 2019-05-03
US20170020859A1 (en) 2017-01-26
EP3180339B1 (en) 2018-12-05
EA031424B1 (ru) 2018-12-28
US9801871B2 (en) 2017-10-31
US20180015082A1 (en) 2018-01-18
DK3180339T3 (en) 2019-03-04
KR102445744B1 (ko) 2022-09-20
IL249844A0 (en) 2017-03-30
CN106573930B (zh) 2020-03-03
NZ728073A (en) 2022-10-28
US10413536B2 (en) 2019-09-17
US20190358218A1 (en) 2019-11-28
LT3180339T (lt) 2019-02-25
CY1121273T1 (el) 2020-05-29
CL2017000326A1 (es) 2017-10-20
CO2017001226A2 (es) 2017-05-10
CN111440164A (zh) 2020-07-24
BR112017002498B1 (pt) 2022-10-11
SG11201700999YA (en) 2017-03-30
JP2017524013A (ja) 2017-08-24
IL249844B (en) 2019-03-31
PH12017500231A1 (en) 2017-07-03
CN106573930A (zh) 2017-04-19
MX2017001835A (es) 2017-04-27
AP2017009718A0 (en) 2017-01-31
HUE043915T2 (hu) 2019-09-30
AU2015303308B2 (en) 2020-01-30
EA201790349A1 (ru) 2017-07-31
EP3180339A1 (en) 2017-06-21
AU2015303308A1 (en) 2017-02-02
CA2956123C (en) 2023-02-14
ES2711763T3 (es) 2019-05-07
UA118887C2 (uk) 2019-03-25
BR112017002498A2 (pt) 2017-12-05
AR101479A1 (es) 2016-12-21
WO2016023858A1 (en) 2016-02-18

Similar Documents

Publication Publication Date Title
TR201902023T4 (tr) Smac mimetikleri olarak 6-alkinil-piridin türevleri.
CY1118859T1 (el) 6-αλκινυλο-πυριδινες ως μιμητες smac
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CY1120935T1 (el) Νεες συνθεσεις, χρησεις και μεθοδοι για την παρασκευη αυτων
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
UY35711A (es) Bis-amidopiridinas como moduladores de la actividad de iap y sus usos como miméticos de smac
PH12015501385A1 (en) Autotaxin inhibitors
NZ724907A (en) Quinoxaline derivatives useful as fgfr kinase modulators
UY35710A (es) 6-alquinilpiridinas como moduladores de la actividad de iap y sus usos como miméticos de smac
MX373320B (es) Compuestos inhibidores de pde2.
TR201819805T4 (tr) Flavaglin türevleri̇.
MX377528B (es) Compuestos de platino funcionalizados con monomaleimida para la terapia del cáncer.
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
DOP2017000058A (es) Derivados de tetrahidroquinolina como inhibidores del bromodominio
MX386761B (es) Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo.
MX379454B (es) Derivados de fluoroindol como moduladores alostéricos positivos del receptor m1 muscarínico.
MX371158B (es) Compuestos inhibidores de pde2.
DOP2016000325A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas
UY34459A (es) Compuestos para tratamiento y prevención de adherencias, composiciones farmacéuticas relacionadas c on los compuestos y métodos para la prevención y tratamiento de adherencias